Skip to main content
. 2023 Jan 20;12(2):164. doi: 10.3390/biology12020164

Figure 2.

Figure 2

Plasma ADAMTS13:AC and VWF:Ag levels. (a) ADAMTS13:AC levels in patients with LC gradually decreased in the order of the non-ACLF group, pre-ACLF group, and post-ACLF group (p < 0.05). (b) VWF:Ag levels in patients with LC gradually increased in the order of the non-ACLF group, pre-ACLF group, and post-ACLF group (p < 0.05). (c) The VWF:Ag/ADAMTS13:AC levels in patients with LC gradually increased in the order of the non-ACLF group, pre-ACLF group, and post-ACLF group (p < 0.05). ACLF, acute-on-chronic liver failure; LC, liver cirrhosis; ADAMTS13, a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC, ADAMTS13 activity; VWF, von Willebrand factor; VWF:Ag, VWF antigen; VWF:Ag/ADAMTS13:AC, the ratio of VWF:Ag to ADAMTS13:AC.